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akuro Shimbo, MD, PHD, Hisayoshi Fujiwara, MD, PHD, for the JSAP (Japanese Stable
ngina Pectoris) Study Investigators
ifu, Japan
bjectives This study sought to determine whether initial medical therapy (MT) only or percutane-
us coronary intervention plus medical therapy (PCIMT) is better for patients with low-risk stable
oronary artery disease (CAD) indicated for intervention in Japan.
ackground Several multicenter studies have suggested that in the above patients, an initial man-
gement strategy of PCIMT does not reduce the long-term risk of cardiovascular events more ef-
ectively than initial MT only.
ethods We conducted a randomized comparative study (JSAP [Japanese Stable Angina Pectoris]
tudy) in the previously mentioned patients.
esults The patients were randomized to PCIMT (n  192) or initial MT only group (n  192),
nd the patient characteristics were very similar in the 2 groups. During the 3.3-year follow-up,
here was no signiﬁcant difference in the cumulative death rate between PCIMT (2.9%) and MT
3.9%). However, the cumulative risk of death plus acute coronary syndrome was signiﬁcantly
maller in PCIMT.
onclusions In stable low-risk CAD, PCIMT may improve long-term prognosis more effectively
han MT. (J Am Coll Cardiol Intv 2008;1:469–79) © 2008 by the American College of Cardiology
oundation
rom the Second Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu City, Gifu, Japan.
ponsorship and oversight of the JSAP Study were provided by a Health and Labour Sciences Research Grant from the Japanese
inistry of Health, Labour, and Welfare and the Japan Heart Foundation (Tokyo, Japan).anuscript received April 10, 2008; revised manuscript received July 25, 2008, accepted August 5, 2008.
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470oronary artery disease (CAD), consisting of stable CAD
nd acute coronary syndrome (ACS) (unstable angina pec-
oris [UAP] and acute myocardial infarction [AMI]), is a
erious and common ailment that can profoundly influence
patient’s prognosis and quality of life. Stable CAD is
lassified into 2 types, depending on the lesion site and the
umber of affected vessels. One type is high-risk CAD,
hich includes 3-vessel disease, left main trunk lesions, and
stial lesions of the left anterior descending artery (LAD)
nd carries a high risk of death. The other type is low-risk
AD and involves disease of 1 or 2 vessels other than those
ssociated with high-risk CAD. This type accounts for the
ajority of CAD patients and carries a low risk of death.
ustification for performing percutaneous coronary interven-
ion (PCI) on patients with stable and low-risk CAD is the
eduction of anginal pain and the prevention of cardiac
events such as ACS and cardiac
death.
See page 480
According to American Col-
lege of Cardiology/American
Heart Association/American
College of Physicians–American
Society of Internal Medicine
guidelines for the treatment of
patients with low-risk stable
CAD (1), which are based on
many multicenter studies (2),
antianginal agents should be ad-
ministered initially to control
anginal attacks, and much effort
should be made toward reduc-
tion of risk factors and lifestyle
intervention. A percutaneous
coronary intervention (PCI)
should be considered only when
edical therapy does not adequately control the symptoms
initial medical therapy [MT] only). Nevertheless, in North
merica, Japan, and elsewhere, PCI combined with medical
herapy has generally been selected as the initial treatment
or low-risk stable CAD (PCI plus medical therapy;
CIMT). Notably in that regard, the COURAGE (Clin-
cal Outcomes Utilizing Revascularization and Aggressive
rug Evaluation) study by Boden et al. (3) recently showed
hat PCIMT does not yield a better long-term prognosis
han initial MT. On the other hand, the SWISSI II (Swiss
nterventional Study on Silent Ischemia Type II) study by
rne et al. (4) reported that PCIMT does indeed improve
rognosis. In addition, the medical therapy in PCIMT
nd in initial MT was intensive in many trials such as the
bbreviations
nd Acronyms
CS  acute coronary
yndrome
MI  acute myocardial
nfarction
AD  coronary artery
isease
AG  coronary
rteriography
I  confidence interval
VA  cerebrovascular
ccidents
CG  electrocardiogram
AD  left anterior
escending artery
T  medical therapy
CI  percutaneous
oronary intervention
AP  unstable angina
ectorisOURAGE study, although PCI plus standard medical therapy has been clinically selected for CAD patients. Thus,
n initial management strategy for low-risk stable CAD has
ot yet been definitively established, especially in Asian
ountries such as Japan.
In the present study, therefore, we conducted a random-
zed trial in which the long-term prognoses obtained with
CIMT and initial MT only, in which medical means
tandard medical therapy, were compared in Japanese pa-
ients with stable low-risk CAD (JSAP [Japanese Stable
ngina Pectoris] Study).
ethods
tudy design. The study protocol was approved by the
uman rights committees at all of the participating institu-
ions, and ample consideration was given to patient privacy.
nly physicians at designated institutions reviewed data,
nd data were obtained directly from those physicians.
edical records were not investigated by a third party.
onsequently, the likelihood of privacy intrusion was very
ow. In this study, 24-h random allocation, data collection,
nd statistical analysis were performed using a host com-
uter in the data center (International Medical Center of
apan [IMCJ], Tokyo, Japan). Discrimination among indi-
idual data was not possible. Computerized data were
rotected by multiple defense systems, and data leakage or
ata correction by individuals other than the physicians in
harge at the institutions was not possible.
This study was performed with written consent of the
atients after informing them of the content, importance,
nd risks of the study, and in the absence of privacy
ntrusion. Whenever a patient expressed a desire to discon-
inue registration, the registration was deleted.
tudy population. Seventy-eight institutions, nationwide,
n Japan that fulfilled the criteria proposed by the Ministry
f Health, Labour, and Welfare for institutions performing
CI were requested to cooperate in the JSAP study (Online
ppendix).
The subjects were patients (age 30 to 75 years) with stable
ow-risk CAD consisting of 1- or 2-vessel disease in whom
oronary arteriography (CAG) showed significant stenosis
75% according to the American Heart Association clas-
ification or 60% on quantitative CAG) at the culprit
esion. A PCI was indicated based on vessel lesion, objective
yocardial ischemia (substantial changes in ST-segment
epression or T-wave inversion on a resting electrocardio-
ram (ECG), or inducible ischemia with either exercise or
harmacologic vasodilator stress), and/or chest pain on
xercise. Exclusion criteria are listed in Table 1. Stable
ngina was defined as angina that was not UAP, which was
efined as rest angina, severe new-onset angina within 2
onths of initial presentation, or worsening angina that was
istinctly more frequent, longer in duration, or lower in
hreshold than before.
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471Patients were randomly allocated to the initial MT only
roup or the PCIMT group so that the 2 groups were
atched with respect to gender, age, risk factors (hyperten-
ion, hyperlipidemia, and diabetes mellitus), and the num-
er of culprit coronary arteries.
egistration methods. The JSAP study was a randomized
omparative study using a host computer in the IMCJ that
nabled 24-h randomized allocation. The registration pe-
iod was 26 months long, extending from February 1, 2002,
o March 31, 2004. When a physician in charge considered
patient to be a candidate for this study, that physician
ould gain access to the JSAP home page by using a
assword provided to each institution and known only by
he data center. The physician could then obtain a tempo-
ary registration, with automatic input of the institution
ame, by inputting the password, an arbitrary 4-digit
dentification number, and the patient’s age and gender.
ubsequently, the study methods were explained to the
atient, and his or her informed consent was obtained.
nitial MT only or PCIMT group was selected after again
ccessing the home page and inputting gender, age, and the
resence or absence of the risk factors (hypertension, hy-
erlipidemia, and diabetes mellitus) and the number of
ulprit coronary arteries. The selection was immediately
isplayed on the screen, and the patient was informed of the
reatment method. With patients who did not give consent
or random allocation, consent to input their data into the
ome page was sought, and the home page was accessed
gain. The reason and the arbitrarily selected treatment
ethod were entered, and symptoms and survival were
valuated after 1 month, 6 months, 1 year, 2 years, and 3
ears (follow-up survey group). When even consent for
nput of data into the home page was denied, the temporary
egistration was deleted. With patients from whom consent
as obtained according to the instructions on the home
age, the final registration was performed by inputting the
Table 1. Criteria for Exclusion From the Japanese Stable Angina
Pectoris Study
High-risk coronary artery disease: 3-vessel disease, lesions in the left main trunk
or ostial left anterior descending artery (within 5 mm of the bifurcation)
Chronic total obstruction
Acute coronary syndrome: myocardial infarction or unstable angina
Left ventricular ejection fraction 50%
Lesions not indicated for percutaneous coronary intervention (thin lateral
branches, peripheral branches, and so on)
Complications such as a tendency to bleed, disseminated intravascular
coagulation, or severe pneumonia
Impaired renal function (creatinine 1.5 mg/dl)
Coronary artery bypass graft surgery patients with graft stenosis as the
responsible lesion
Low-risk coronary artery disease patients for whom percutaneous coronary
intervention plus medical therapy or initial medical therapy only had already
been prescribed by a previous physicianlassification of their angina symptoms, the oral medicationseing taken, and the findings of CAG. Additional input of
ata to the home page was performed periodically, as
ecessary.
linical outcome. Clinical outcome was adjudicated by an
ndependent outside committee whose members were un-
ware of the treatment assignment (Online Appendix: JSAP
tudy Evaluation Committee). The primary end points
ere death (total death, cardiac death, and sudden death),
CS (AMI or UAP), cerebrovascular accidents (CVA;
erebral infarction or cerebral hemorrhage), and emergency
ospitalization. The secondary end point was evaluation of
he angina severity grade 1 month, 6 months, 1 year, 2 years,
nd 3 years after registration (Table 2), and elective repeat
evascularization.
We defined ACS as AMI or UAP requiring emergency
ospitalization, which is caused by the same mechanisms:
laque rupture, intimal erosion, and/or thrombus formation
n a coronary artery. Patients who received elective PCI for
ncontrollable angina in the initial MT group or for
estenosis after PCI in the PCIMT group were excluded
rom the ACS patients.
An AMI was definitively diagnosed if new abnormal Q
aves appeared in 2 or more ECG leads during follow-up,
r if a convincing clinical history was associated with ECG
hanges compatible with non–Q-wave infarction, and the
erum activities of at least 2 cardiac enzymes were greater
han twice normal. A UAP was defined as emergency
dmission for ischemic cardiac pain associated with ECG
igns of myocardial ischemia and presentation of coronary
tenosis of 90% on CAG in the absence of elevation of
erum cardiac enzymes to more than twice normal or the
ppearance of new Q waves. A CVA was defined as a
udden focal disturbance in brain function of presumed
ascular origin persisting for longer than 24 h. Hospitaliza-
ion was defined as the state to require intensive care by
mergency hospitalization on the JSAP study, for example,
evere heart failure, critical arrhythmia, and so on.
rugs and intervention methods. For each patient in the
CIMT and initial MT groups, medical therapy with
ntiangina and antirisk factor drugs that was based on
vidence from the patient was recommended to the physi-
ian in charge. In both groups, the physician in charge could
Table 2. Classification of Severity of Angina*
Class 0: No angina, even during strenuous or prolonged physical activity
Class 1: Angina only during strenuous or prolonged physical activity
Class 2: Slight limitation, with angina only during vigorous physical activity
Class 3: Symptoms during occasional living activities, i.e., mild limitation
Class 4: Symptoms during everyday living activities, i.e., moderate limitation
Class 5: Inability to perform any activity without angina or angina at rest,
i.e., severe limitation*Canadian Cardiovascular Society classification was modified.
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472dd to or change the prescription at his or her discretion to
elieve the signs and symptoms of the patients.
There were no restrictions on the device used for PCI,
ut the use of a stent was recommended. Drug-eluting
tents were not used, however, because at the time of the
tudy they were not yet covered by insurance in Japan.
In Japan, follow-up CAG is performed in nearly all PCI
atients 3 to 12 months after PCI, whether or not ischemic
igns and/or symptoms are present. Generally, PCI is added
hen restenosis at the PCI site and/or new significant
tenosis at a non-PCI site are found on the follow-up CAG.
he same procedures were followed for patients in the
CIMT group. In the initial MT group, myocardial
evascularization procedures were reserved for patients
hose symptoms were not adequately controlled by inten-
ive medical therapy. In addition, follow-up CAG within 1
r 2 years was recommended in the group.
tatistical analysis. In the RITA-2 (Second Randomised
ntervention Treatment of Angina) trial (5), the hazard
atio of the PCIMT to the intitial MT group was 1.92
ith a 95% confidence interval (CI) 1.08 to 3.41 (p  0.02)
in all-cause death plus nonfatal AMI), and the event rate
er 5 years was 15% with PCIMT and 8% with initial
T. If this was applied to the present study, which had 384
articipating patients, an expected event number of 74 and
follow-up period extending until September 2010 would
e needed to keep the power at 80% (  0.05,   0.2).
owever, the primary end points in the JSAP study were all
auses of death plus ACS plus cerebrovascular accident plus
mergency hospitalization. Therefore, independent JSAP
tudy statistics and JSAP study evaluation committees
erformed an interim analysis in May 2006 (mean
ollow-up period: 3.3 years). The result showed the number
f events to be 103 with a power point of 90%, and the
ifference in the primary end points between the PCIMT
nd initial MT groups was significant (p  0.05). Conse-
uently, further follow-up was deemed unnecessary. Based
n the above interim analysis, those committees recom-
ended stopping the follow-up because continuing the
SAP study might not benefit the prognosis of patients in
he initial MT group.
The cumulative event rate was calculated using the
aplan-Meier method, and the 2 groups were compared
sing the log rank statistic. The treatment effects on the
azard ratio and its associated 95% CI were estimated using
he Cox proportional hazards model. Data collection and
tatistical analyses were entrusted to the IMCJ. Analyses
ere performed according to the intention-to-treat princi-
le. Categorical variables were compared using the chi-
quare test; continuous variables were compared using the
npaired Student t test or Wilcoxon test. A significance
evel of 0.05 was used for all subgroup analyses and
nteractions.rganization of evaluation committee. The JSAP study was
valuated by a committee consisting of a central chairper-
on, central committee members, statistics committee mem-
ers, and outside committee members independent of the
tudy (Online Appendix).
esults
aseline characteristics and angiographic data. Between
ebruary 1, 2002, and March 31, 2004, a total of 469
atients were enrolled in this study at 78 institutions,
ationwide, in Japan (Fig. 1). Of those, 85 did not give
onsent for random allocation but did give consent to input
heir data into the home page; the reason and the arbitrarily
elected treatment method were entered, and their symp-
oms and survival were evaluated after 1 month, 6 months,
year, 2 years, and 3 years (follow-up survey group). The
emaining 384 patients, from whom informed consent was
btained, were randomly allocated to the initial MT group
n  192) or the PCIMT group (n  192).
This report concerns follow-up to May 31, 2006, which
as completed for 98.7% of the patients (379 of 384
atients: 4 of 192 in the PCIMT group and 1 of 192 in
469 met eligibility criteria 
85 declined to give 
permission
384 consented to participate 
(82% of patients with protocol eligibility)
192 were assigned to initial 
medical therapy only group 
70 (36.5%) underwent 
additional elective PCI 
192 were assigned to 
PCI plus medical group, 
and underwent initial 
elective PCI
41 (21.4%) underwent 
additional elective PCI* 
192 were included in the 
primary analysis 
192 were included in the 
primary analysis 
Figure 1. Enrollment of the Patients and the Outcomes
Note that additional elective percutaneous coronary intervention (PCI) was
signiﬁcantly lower in the PCI plus medical group than the initial medical
therapy only group. *The percentage of repeat revascularization in the PCI
plus medical group was signiﬁcantly lower than that in the initial medical
therapy only group (p  0.001).
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473he initial MT group were dropped). The minimum and
verage follow-up periods were 126 days and 1,187  252
ays, respectively (mean  SD; median: 3.3 years, inter-
uartile range: 2.9 to 3.8 years, average: 3.2 years, 95% CI:
.14 to 3.29 years).
The characteristics of the patients in the 2 groups are
hown in Table 3. Overall, there was close similarity
etween the initial MT and PCIMT groups with respect
o age, gender, risk factors, number of affected vessels, and
o on. The percentage of patients with class 0 angina (no
ngina, even during strenuous or prolonged physical activ-
ty) on the classification of severity of angina scale at the
ime of randomization was 12.9% in the initial MT group
nd 11.7% in the PCIMT group.
The distribution of underlying diseases such as hyperten-
ion, hyperlipidemia, and diabetes mellitus was also similar
n the 2 groups. A previous MI had occurred in 15.1% of
atients in the initial MT group and in 14.0% of patients in
he PCIMT group. Patients with previous coronary artery
ypass grafting were rare in both groups (1.6% in the initial
T group and 2.8% in the PCIMT group). In both
roups, approximately two-thirds of the patients had
-vessel disease, and the remaining one-third had 2-vessel
isease.
edication and treatment. Clinical status, risk and life-
tyle, and the type of medications used are shown in Table
. Mean systolic and diastolic blood pressures during
ollow-up were controlled at 128 to 135 mm Hg and 73 to
5 mm Hg, respectively, in both the PCIMT and initial
T groups. During follow-up, the mean serum total
holesterol level was 183 to 192 mg/dl in both groups and
emoglobin-A1C was 6.2 to 6.4 in each group.
At entry into the study, serum total cholesterol and
ow-density lipoprotein cholesterol were significantly higher
n the PCIMT group than in the initial MT group, and
he number of current smokers was higher in the initial MT
roup than in the PCIMT group. However, these differ-
nces were not seen after 6 months, 1 year, and 3 years of
ollow-up.
There were no significant differences in the use of
edication between the initial MT and PCIMT groups
fter randomization or during follow-up, except for nitrate,
hich was used less in the PCIMT group at the 6-month,
-year, and 3-year follow-ups.
ntended randomized PCI. Intended randomized PCI was
erformed in all patients in the PCIMT group. The average
ime from randomization to PCI was 33 days; 31% of PCIs
ere performed within 1 week, 66% within 1 month, and 91%
ithin 3 months of randomization. The initial success rate was
9.5% for a total of 209 vessel segments. Only 1 case was
nsuccessful (from 75% stenosis to 75% stenosis angiographi-
ally). On average, the degree of stenosis improved from 86
% before PCI to 5  11% after PCI in stent-treated vessels
25% in each) and from 87  10% to 24  15% inTable 3. Baseline Clinical and Angiographic Characteristics
Initial MT
Only Group
(n  192)
PCIMT
Group
(n  192)
p
Value
Characteristic
Age, yrs 64.2 7.6 64.5 7.2 0.755
Minimum, median, maximum 41, 65, 75 41, 65, 75
65 yrs, n (%) 90 (47.2) 87 (46.3) 0.869
Male, n (%) 144 (75.4) 141 (75.0) 0.930
Physique
Height, cm 160.4 8.4 160.2 8.3 0.784
Weight, kg 62.3 9.8 62.6 10.5 0.818
Body mass index, kg/m2 24.1 2.8 24.3 3.3 0.574
Clinical
Initial angina grade, n (%) 0.396
0* 24 (12.9) 21 (11.7)
1 69 (37.1) 64 (35.8)
2 74 (39.8) 68 (38.0)
3 16 (8.6) 19 (10.6)
4 3 (1.6) 6 (3.3)
5 0 (0.0) 1 (0.6)
Missing data 6 13
History, n (%)
Diabetes 76 (39.8) 76 (40.4) 0.900
Hypertension 121 (63.4) 119 (63.3) 0.992
Hyperlipidemia 121 (63.4) 120 (63.8) 0.923
Hyperuricemia 24 (12.9) 20 (11.2) 0.612
Menopause of female 29
(61.7 of female)
31
(66.0 of female)
0.668
Myocardial infarction 28 (15.1) 25 (14.0) 0.768
Previous PCI 54 (29.0) 44 (24.6) 0.337
CABG 3 (1.6) 5 (2.8) 0.441
Cerebrovascular disease 10 (5.4) 13 (7.3) 0.459
Stress test, n (%)
Total patients 149 (80.1) 146 (81.6) 0.724
Treadmill test 76 (40.9) 68 (38.0) 0.575
Duration of treadmill test, min,
n (%)
7.0 3.5 6.4 2.7 0.255
Nuclear medicine 55 (29.6) 63 (35.2) 0.251
Echocardiography 13 (7.0) 13 (7.3) 0.919
Angiographic
Vessels with disease, n (%) 0.998
1 129 (67.5) 127 (67.6)
2 62 (32.5) 61 (32.5)
Ejection fraction 65.8 9.6 64.0 9.7 0.171
Cardiac index 3.1 0.8 3.1 0.8 0.742
Plus-minus values aremean SD. *These includedpatientswith any arrhythmia, untypical chest
discomfort, or dyspnea on effort, and asymptomatic patients with any abnormal cardiac
findings on mass examination, among others. Objective myocardial ischemia (substantial
changes in ST-segment depression or T-wave inversion on a resting electrocardiogram, or
inducible ischemiawith either exercise or pharmacologic vasodilator stress) was found in all of
these patients, after which coronary arteriography showed 1- or 2-vessel disease in each.
CABG coronary artery bypass grafting; MTmedical therapy; PCI percutaneous coronary
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474onstent-treated vessels (50% in each except for 1 vessel with
nsuccessful PCI). Seventy-six percent of PCIs were per-
ormed with coronary bare-metal stents and 15% with plain
alloon angioplasty. A cutting balloon was used in 10% of
ases, directional atherectomy in 5.9%, and rotational atherec-
omy in 5.3%.
rimary and secondary end points. There were no deaths
ithin 7 days after PCI among the 192 patients who received
CI; ACS occurred in 1 patient within 7 days after PCI.
Kaplan-Meier survival curves for the primary end point
Table 4. Clinical Status, Risk and Life-Style, and Use of Medication
Variable
Initial MT Only Group (n  192)
Baseline 6 Months 1 Yr
Clinical status
No. evaluated 192 181 172
Blood pressure, mm Hg
Systolic 140 24 132 17 132 17 13
Diastolic 73 13 74 10 74 10 7
Heart rate, beats/min 68 12 68 11 68 10 6
Cholesterol, mg/dl
Total 196 37 186 36 186 31 18
LDL 116 32 109 33 110 26 10
HDL 49 15 48 11 49 13 5
Triglycerides, mg/dl 153 95 143 79 145 86 13
Uric acid, mg/dl 5.7 1.5 5.7 1.5 6.0 2.2 5
Risk or life-style factor
Current smoker, % 23.7 12.4 12.6
Fasting blood sugar 123 45 129 52 131 51 12
HbA1c 6.2 1.2 6.2 1.0 6.2 1.0 6
Patients with diabetes
No. evaluated (FBS) 67 48 46
No. evaluated (HbA1c) 66 53 49
Fasting blood sugar 156 54 159 65 163 64 15
HbA1c 7.0 1.2 6.7 1.0 6.8 1.0 6
Other laboratory data
RBC 438 44 441 50 434 49 42
WBC 6,210 1,496 6,207 1,761 5,863 1,476 5,78
Hb 13.8 1.4 13.7 1.5 13.6 1.4 13
Ht 40.9 4.0 40.8 4.9 40.8 3.9 40
Platelet 22.4 6.5 21.4 6.0 20.9 5.5 21
BUN 16.1 4.2 16.4 4.2 16.0 4.2 16
Cr 0.83 0.21 0.82 0.21 0.82 0.23 0.9
AST 26 14 25 11 28 26 2
ALT 28 19 26 16 25 19 2
LDH 236 103 233 96 229 91 20
gamma-GTP 57 77 66 108 64 112 5
ALP 222 87 230 84 222 74 25
CRP 0.22 0.44 0.21 0.65 0.28 0.65 0.1
CPK 110 61 109 71 113 81 12re shown in Figure 2. During the 3.3-year follow-up, Mhere was no significant difference in the survival curves
ree of all causes of death between the initial MT and
CIMT groups. However, the survival curve free of all
auses of death and ACS in the PCIMT group was
hifted significantly upward relative to that in the initial
T group. In addition, the survival curves free of all
auses of death, ACS, and cerebral vascular accidents,
nd free of all causes of death, ACS, cerebral vascular
ccidents, and emergency hospitalization were each sig-
ificantly higher in the PCIMT group than the initial
PCIMT Group (n  192)
p Value
Baseline 6 Months 1 Yr 3 Yrs Baseline
Through
3 Yrs*
192 168 158 106
142 25 136 19 133 17 135 14 0.344 0.401
73 12 75 10 74 10 75 9 0.704 0.334
69 11 69 11 70 10 69 10 0.290 0.469
206 43 192 35 193 36 183 27 0.038 0.328
125 32 113 31 115 33 106 26 0.007 0.354
48 13 49 14 50 15 51 12 0.349 0.123
167 171 153 103 136 102 144 69 0.429 0.278
5.7 1.4 5.7 1.4 5.8 1.3 5.7 1.5 0.607 0.057
13.1 8.9 7.4 5.2 0.009 0.079
122 44 120 47 120 40 126 48 0.656 0.550
6.3 1.3 6.2 1.3 6.3 1.4 6.3 1.3 0.637 0.635
67 54 41 26
67 55 41 24
152 53 143 60 151 48 155 64 0.664 0.390
7.0 1.2 6.9 1.3 7.1 1.4 7.4 1.2 0.512 0.620
442 52 432 50 435 50 434 47 0.393 0.581
71 6,201 1,319 6,029 1,384 5,874 1,325 5,831 1,339 0.872 0.570
13.7 1.8 13.5 1.6 13.6 1.6 13.5 1.5 0.705 0.417
40.8 5.2 40.3 4.5 40.6 4.6 40.6 4.3 0.753 0.445
21.8 5.8 21.7 6.4 21.2 5.7 20.3 5.8 0.624 0.801
16.0 5.3 16.4 4.5 16.3 4.7 16.8 5.1 0.355 0.933
3 0.86 0.37 0.84 0.25 0.86 0.26 0.85 0.28 0.951 0.606
27 20 25 11 27 28 27 15 0.681 0.087
27 17 27 17 26 15 28 23 0.623 0.198
239 102 231 107 224 93 207 58 0.616 0.232
50 75 52 60 51 75 52 91 0.287 0.647
228 96 222 87 224 80 249 103 0.488 0.304
7 0.28 0.61 0.20 0.46 0.20 0.63 0.18 0.31 0.260 0.150
103 57 105 62 109 69 117 82 0.233 0.137
Continued on next page3 Yrs
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475The cumulative death rate at 3.3 years was 3.9% in the
nitial MT group and 2.9% in the PCIMT group, which
as not a significant difference (Table 5). In addition, there
as no significant difference in the rates of cardiac death,
ncluding sudden death, or noncardiac death between the 2
roups. On the other hand, ACS occurred significantly less
requently in the PCIMT group (cumulative rate at 3.3
ears: 5.0%) than in the initial MT group (11.7%). Al-
hough there was no significant difference in the cumulative
ates of nonfatal AMI between the PCIMT and initial
T groups (1.6% vs. 3.7%, respectively), the rate of UAP
as significantly lower in the PCIMT group than in the
nitial MT group (3.2% vs. 7.3%, respectively). Likewise,
he rate of emergency hospitalization was significantly lower
n the PCIMT group (20.6%) than the initial MT group
31.6%). All of the emergency hospitalizations were attrib-
table to ACS or CVA; none were attributable to heart
ailure or arrhythmia. There was no significant difference in
he rates of CVA between the 2 groups (Table 5).
As shown in Figure 3, the severity of angina symptoms,
hich was similar in the initial MT and PCIMT groups
t entry into the study, was much reduced in both groups
Fig. 3). However, the severity was significantly lower in the
CIMT group than the initial MT group at the 1-month,
-month, 1-year, 2-year, and 3-year follow-ups in overall
nd both mild and severe initial symptoms groups.
In the present study, elective repeat revascularization was
Table 4. Continued
Variable
Initial MT Only Group (n  192)
Baseline 6 Months 1 Yr
Medication
No. evaluated 186 181 172
Aspirin or other antiplatelet, n (%) 170 (91.4) 171 (94.5) 160 (93.0) 1
Warfarin, n (%) 2 (1.1) 2 (1.1) 3 (1.7)
Calcium-channel blocker, n (%) 109 (58.6) 113 (62.4) 109 (63.4)
KATP-channel opener, n (%) 47 (25.3) 51 (28.2) 44 (25.6)
Beta-blocker, n (%)† 96 (51.6) 96 (53.0) 93 (54.1)
Alpha-blocker, n (%) 9 (4.8) 9 (5.0) 8 (4.7)
Nitrates, n (%) 106 (57.0) 108 (59.7) 101 (58.7)
Diuretics, n (%) 13 (7.0) 12 (6.6) 16 (9.3)
ACE inhibitor, n (%) 26 (14.0) 26 (14.4) 25 (14.5)
ARB, n (%) 47 (25.3) 48 (26.5) 50 (29.1)
Statin, n (%) 84 (45.2) 91 (50.3) 93 (54.1)
Other antilipid, n (%) 13 (7.0) 13 (7.2) 11 (6.4)
Plus-minus values aremeans SD. *The interaction between treatment and timewas tested in repe
frequency in side effects such as heart failure and bradycardia, beta-blockade is not used in Japan a
study, compared with the COURAGE study.
ACE angiotensin-converting enzyme; ALP alkaline phosphatase; ALT alanine aminotransfe
CPK creatine phosphokinase; Cr creatinine; CRP C-reactive protein; FBS fasting blood suga
high-density lipoprotein; Ht hematocrit; KATP adenosine triphosphate-dependent potassium;
cells; other abbreviations as in Table 3.erformed in 21.4% of patients in the PCIMT group, but 1lective revascularization was needed in 36.5% of patients in
he initial MT group (Fig. 1). This difference was significant
p  0.0011). Likewise, the frequency of emergency revas-
ularization during an attack of ACS was also significantly
ower in the PCIMT group (5%) than the initial MT
roup (12%) (Table 5).
CS and ACS-related coronary lesions. Emergency CAG
fter an attack of ACS was performed in 32 patients in
hom ACS developed during 3.3-year follow-up. As shown
n Table 5, the percentage of patients with ACS originating
rom a lesion that had caused significant stenosis at entry
nto the JSAP study was significantly lower in the
CIMT (3.2%) than in the initial MT (8.8%) group. On
he other hand, there was no significant difference between
he 2 groups in the percentages of patients with ACS
riginating from a lesion other than the initial target lesion
oted at entry. In the initial MT group, the percentage of
atients with ACS originating from a site that had shown
ignificant stenosis at entry was significantly higher (8.8%)
han that from a different site (4.3%). In the PCIMT
roup, however, there was no significant difference between
he percentages of ACS originating from the initial target
esion at entry and other sites.
For those in the PCIMT group with ACS originating
rom the initial target site, the degree of stenosis in the
CS-related coronary artery was 81.5 10.5% at entry into
he study, before the first PCI; it was reduced to 8.3 
PCIMT Group (n  192)
p Value
Baseline 6 Months 1 Yr 3 Yrs Baseline
Through
3 Yrs*
181 168 158 107
) 166 (91.7) 164 (97.6) 153 (96.8) 101 (94.4) 0.914 0.197
7 (4.2) 6 (3.6) 6 (3.8) 6 (5.6) 0.101 0.307
) 103 (56.9) 96 (57.1) 86 (54.4) 53 (49.5) 0.742 0.145
) 40 (22.1) 37 (22.0) 36 (22.8) 24 (22.4) 0.475 0.121
) 79 (43.6) 82 (48.8) 76 (48.1) 50 (46.7) 0.126 0.129
9 (5.0) 9 (5.4) 9 (5.7) 5 (4.7) 1.000 1.000
) 93 (51.4) 80 (47.6) 70 (44.3) 39 (36.4) 0.281 0.009
8 (4.4) 11 (6.5) 12 (7.6) 11 (10.3) 0.289 0.673
) 39 (21.5) 35 (20.8) 34 (21.5) 22 (20.6) 0.058 0.068
) 37 (20.4) 42 (25.0) 42 (26.6) 37 (34.6) 0.271 0.610
) 89 (49.2) 100 (59.5) 98 (62.0) 70 (65.4) 0.442 0.138
10 (5.5) 13 (7.7) 11 (7.0) 3 (2.8) 0.563 0.208
easurementMANOVA for complete cases in vital signs and laboratory results. †Because of the high
as in western countries. This is reflected by the lower frequency of beta-blockade in the JSAP
B angiotensin receptor blocker; AST aspartate aminotransferase; BUN blood urea nitrogen;
a-GTP gamma-glutamyl transpeptidase; Hb hemoglobin; HbA1C hemoglobin-A1C; HDL
lactate dehydrogenase; LDL low-density lipoprotein; RBC red blood cells; WBCwhite blood3 Yrs
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476he time of the ACS attack. For those with ACS originating
rom a nontarget lesion, the degree of stenosis was 16.7 
8.9% at entry, but it had progressed to 93.0  5.2% by the
ime of ACS attack. For those in the initial MT group with
CS originating from a coronary site that showed signifi-
ant stenosis at entry, the degree of stenosis in the ACS-
elated coronary artery had progressed significantly from
9.3  6.7% at entry to 95.1  6.9% at the time of ACS
ttack. For those with ACS originating from a coronary site
hat did not show significant stenosis at the entry, the
egree of stenosis progressed from 32.1  12.2% at entry to
4.6  9.3% at the time of ACS attack.
iscussion
eduction of ACS in the PCIMT group. Studies carried out
n Western countries have generally found that long-term
rognoses with respect to death or ACS are not significantly
0.7
0.8
0.9
1.0
0 1 2 3 4 5
<HDUV
0.7
0.8
0.9
1.0
0 1 2 3 4 5
<HDUV
Initial medical therapy only
PCI plus medical therapy
Death
Hazard ratio, 0.865; 95% CI (0.278-2.604)
P=0.794
Death+ACS+CVA
Hazard ratio, 0.541; 95% CI (0.287-0.983)
P=0.045
Initial-Medical 188   188           180            133            19 
PCI+Medical   186   186           178            131            17   
Initial-Medical* 182   177           166            115            18 
PCI+Medical*    183   179           170            123            15   
0
0
A
C
Initial medical therapy only
PCI plus medical therapy
Figure 2. Kaplan-Meier Survival Curves for the Primary End Point
Note that the survival curves free of all causes of death (Death)  acute coron
 ACS  CVA  Hospitalization (emergency hospitalization) in the PCI plus m
therapy only group, although Death was similar in the 2 groups. *The number
only groups. Abbreviations as in Figure 1.etter with PCIMT than with initial MT (2,3,5). In the iresent study, however, the cumulative rate of cardiac events
e.g., ACS) was smaller in the PCIMT group than the
nitial MT group, although there was no significant differ-
nce on death. This finding is consistent with those of the
WISSI II study (4), which reported that PCIMT
educed the long-term risk of major cardiac events in
atients with silent MI after MI.
For the patients in the present study, who had 1- or
-vessel disease, the cumulative rate of ACS during the
.3-year follow-up was 5.0% in the PCIMT group and
1.7% in the initial MT group. In the RITA-2 trial (5), in
hich most of the patients had 1- or 2-vessel disease, the
umulative rates of ACS in the PCIMT and initial MT
roups were 13.6% and 11.4%, respectively, during the
.7-year follow-up. In the COURAGE trial (3), in which
pproximately one-third of the patients had 3-vessel disease,
he cumulative rates of ACS were 20.0% and 18.7%,
espectively, during the 4.6-year follow-up. Thus, the key
nding of the present study is the clear reduction of the
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Hazard ratio, 0.474; 95% CI (0.243-0.881)
P=0.019
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Hazard ratio, 0.664; 95% CI (0.446-0.981)
P=0.040
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ndrome (ACS), Death  ACS  cerebrovascular accidents (CVA), and Death
therapy group was shifted signiﬁcantly upward to that in the initial medical
tients in each of the PCI plus medical therapy and initial medical therapyIni
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477ossible mechanism underlying the reduced ACS in the
CIMT group. In Table 3, use of nitrates was significantly
maller in the PCIMT group than in the initial MT
roup, suggesting it is unrelated with the reduction in ACS
n the PCIMT group. Other variables showed no signif-
cant difference. Thus each of the variables in Table 3 seems
o be independent of the beneficial effect seen in the
CIMT group.
Two types of ACS occurred in patients entered into this
tudy. One type was caused by progression of a PCI target
esion already showing significant stenosis at the time of
ntry to more severe stenosis as a result of thrombus
ormation via plaque rupture detected at the time of ACS
nset during the follow-up. The PCI target lesion was
reated with PCI at entry in the PCIMT group, but not
n the initial MT group. If a patient at entry had an acute
cclusion or rapidly narrowing lesion, then he or she would
ot have met the study’s inclusion criteria as a low-risk and
table patient. The second type was caused by progression of
non-PCI target lesion at entry to severe stenosis by
hrombus formation via plaque rupture. We found that the
ncidence of ACS stemming from the PCI target lesion was
ignificantly lower in the PCIMT group than the initial
T group. Moreover, a number of studies, including those
y Cutlip et al. (6) and Kimura et al. (7), have shown that
he PCI target lesion may remain stable for more than 1 year
fter PCI. Therefore, the reduced incidence of ACS stem-
Table 5. Estimate of the Hazard Ratio for the Primary Efficacy Outcome M
Outcome
Number of Events
Initial MT
Only Group
(n  191)
PC
G
(n 
Deaths 7
Cardiac 3
Noncardiac 4
Unknown 0
Death and ACS 29
Death, ACS, and stroke 29
Death, ACS, stroke, and emergency hospitalization 61
ACS 23
Myocardial infarction 7
Unstable angina 16
Originating from target lesion* 16
Originating from nontarget lesion 7
CVA 2
Cerebral infarction 2
Cerebral hemorrhage 0
Emergency hospitalization 58
*PCI target site of coronary artery with significant stenosis at the entry into Japanese Stable Angina
ACS acute coronary syndrome; CVA cerebrovascular accident; other abbreviations as in Tabing from the PCI target lesion in the PCIMT group cay be caused by stabilization of PCI target coronary artery
y PCI.
Generally, vulnerable plaques (ACS precursors) have a
hinner fibrous cap and a larger lipid core than stable
laques and do not cause significant stenosis before they
upture, precipitating ACS. By contrast, stable plaques may
arrow the coronary lumen and produce ischemia and
nginal symptoms but are less likely to result in ACS. This
as been claimed as the main reason why focal management
f coronary lesions with significant stenosis using PCI does
ot improve long-term prognosis. That explanation is
oubtful, however, because: 1) approximately one-third of
MIs stem from a coronary site that already shows signif-
cant stenosis (8); 2) approximately 40% of ACS cases
bserved during an 8-month follow-up reportedly origi-
ated from the PCI target lesion in patients with stable
ngina pectoris (9), and in approximately 40% of ACS cases
riginating from a non-PCI target lesion, the ACS-related
ite already had significant stenosis at the initial PCI (10);
nd 3) because of the widespread use of PCI to treat
ow-risk angina, there have been no reliable comparative
tudies of the rates of ACS originating from PCI target and
on-PCI target lesions in the initial MT group. In fact, that
nalysis was omitted in earlier multicenter studies, such as
he RITA-2 and the COURAGE trials. In the present
nitial MT group, more than one-half of ACS originated
rom the PCI target lesion. Thus, the present finding that a
onsiderable number of ACS cases may originate from
s
Hazard Ratio
(95% CI) p Value
Cumulative Rate at 3.3 Yrs
)
Initial MT
Only Group
(%)
PCIMT
Group
(%)
0.865 (0.278–2.604) 0.794 3.9 2.9
0.474 (0.243–0.881) 0.018 14.9 7.9
0.541 (0.287–0.983) 0.044 16.4 8.5
0.664 (0.446–0.981) 0.040 33.2 22
0.384 (0.168–0.802) 0.012 11.7 5.0
0.429 (0.092–1.542) 0.200 3.8 1.6
0.370 (0.133–0.899) 0.028 8.9 3.4
0.373 (0.134–0.907) 0.029 8.8 3.2
0.408 (0.088–1.470) 0.175 4.3 1.9
1.028 (0.123–8.561) 0.978 1.1 0.6
0.658 (0.435–0.983) 0.042 31.6 20.6
s Study.easure
IMT
roup
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478ble to expect that PCI therapy would protect against a
uture ACS attack by stabilizing the PCI target lesion as
ell as reducing stenosis.
The lower frequency of ACS in the PCIMT group is
ompatible with that of the SWISSI II study but not with
he majority of studies in the published literature, including
he COURAGE trial, the RITA-2 trial, and the meta-
nalysis by Katritsis et al. (2). Possible explanations for this
iscrepancy may be as follows. Kaplan-Meier event-free
urvival curves for the PCIMT groups in the COURAGE
0
1
2
3
-1
0
1
2
3
-1
0
1
2
3
-1
4
Baseline
1mo 6mo
Initial medical therapy only
PCI plus medical therapy
Overall#
**
1Yr 2Yr 3Yr
Mild symptom
(Angina grade 0-2)
Severe symptom
(Angina grade 3-5)
**
**
**** *
****
**
Figure 3. Changes in the Severity of Angina Symptoms During the
Follow-Up
Note that the severity was signiﬁcantly lower in the PCI plus medical ther-
apy group than in the initial medical therapy only group. *p  0.05.
**p  0.01 vs. the PCI plus medical therapy group. #Overall, the interaction
between treatment and time was tested in repeated-measurement multi-
variate analysis of variance for complete cases. After missing observations
were imputed using the last observation carried forward method, the
p value was 0.0001. Abbreviations as in Figure 1.nd RITA-2 trials seem to show curious biphasic changes Phat are clearly different from those obtained in the present
tudy and the SWISSI II study, although we have no data
ith which to determine whether the biphasic changes were
tatistically significant. In the COURAGE and RITA-2
rials, there seems to be a marked downward shift in the
urves for the PCIMT group relative to those for the
nitial MT group during the initial 4 months, and this
ownward shift gradually disappeared in the later stages of
he follow-up period. By contrast, such biphasic changes in
he Kaplan-Meier event-free survival curves were not seen
n the present study or the SWISSI II study; instead, the
urve for the PCIMT group was shifted upward relative
o that of the initial MT group at the initial stage of
ollow-up, and that upward shift became greater at the later
tages. If cardiac events occurring during the early stages are
xcluded, the incidence of late cardiac events would be
maller in the PCIMT group, even in the COURAGE
nd RITA-2 trials, and the data from the late stages support
he idea expressed in the present study; that is, PCIMT
reatment can improve long-term prognosis, probably by
tabilizing the plaque at the PCI site. In addition, we
uggest that a device such as the drug-eluting stent, which
an strongly protect against cardiac events early after PCI
11,12), may further improve the total long-term prognosis
btained with PCIMT, compared with that obtained with
nitial MT treatment.
We will now consider the increased incidence of ACS
arly during follow-up in the PCIMT group in the
ITA-2 study and the COURAGE study, which was
ndicated by the marked downward shift of the Kaplan-
eier curve (ACS incidence in the PCIMT group at 4
onths after PCI: 1% in the JSAP study vs. approximately
% in the COURAGE study; in the initial MT group: 3%
n the JSAP study vs. approximately 4% in the COURAGE
tudy). In the RITA-2 study, the increase in ACS during
he initial stage of follow-up could be explained by technical
roblems with the stents, which were used only rarely at that
ime but had become popular by the time of the present
tudy. In addition, patients with 3-vessel disease were
ncluded in the COURAGE study (approximately one-
hird), and it is now established that 3-vessel disease is the
ost important risk factor for cardiac events after PCI (6,7).
ll of the subjects in the present study were stable CAD
atients with 1- or 2-vessel disease, so that differences in the
ackgrounds of the patients may have contributed to the
ower incidence of ACS seen in the present study, compared
ith the COURAGE study. Follow-up CAG is routinely
arried out 3 to 12 months after PCI in Japan, which may
e important for prevention of ACS. However, the marked
ownward shift of the Kaplan-Meier curve seen in the
ITA-2 and COURAGE studies occurred within 3
onths after PCI. In addition, the follow-up CAG was
erformed in both groups in the JSAP study (100% in the
CIMT group and 96% in the initial MT group).
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479herefore, it would not serve to offset the difference
etween the 2 groups in the JSAP study.
Finally, we will discuss PCI carried out under intravas-
ular ultrasound (IVUS), which can enable prediction of
nd protection from various complications such as subacute
hrombosis after PCI (13). In Japan, PCI is generally
erformed under IVUS. In the present study, this was true
or all of the patients in the PCIMT group, but it is not
lways true in the U.S. and elsewhere. The initial success
ate per vessel for PCI was higher in the JSAP trial (99.5%)
han in the COURAGE trial (93%), despite similar reduc-
ions in stenosis achieved with PCI (from 86% to 5% vs.
rom 82% to 2% in stent-treated vessels, and from 87% to
4% vs. from 83% to 31% in nonstent-treated vessels,
espectively). Perhaps the better initial success rate in the
SAP trial reflects differences in the technical aspects of the
CI procedure (e.g., whether the PCI was IVUS-guided)
ather than the degree of coronary atherosclerosis. Thus, the
ackgrounds of the patients and the PCI procedure may be
mportant contributors to the differences between the
resent study and the RITA-2 or the COURAGE trial.
tudy limitations. This study was not blinded. To limit the
isk of bias, the patients were randomized by computer,
bjective outcomes were used, and a committee blinded to
he treatment groups adjudicated the end points and based
ts decisions on hospital case records from other physicians
ot involved in the study.
In addition, despite formal power calculations, the sample
ize was relatively small. However, the follow-up was
omplete for 98.7% of the patients, which is very high
ompared with the 91% in the COURAGE trial, and the
ifference between the PCIMT and initial MT groups
as significant.
onclusions
n patients with low-risk CAD, PCIMT treatment may
mprove long-term prognosis more effectively than initial
T treatment.
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